Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

BACKGROUND: To evaluate health-related quality of life (HRQL) and medication satisfaction after switching from a stable dose of oral extended-release methylphenidate (ER-MPH) to methylphenidate transdermal system (MTS) via a dose-transition schedule in children with attention-deficit/hyperactivity d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bukstein, Oscar G, Arnold, L Eugene, Landgraf, Jeanne M, Hodgkins, Paul
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796990/
https://www.ncbi.nlm.nih.gov/pubmed/20003260
http://dx.doi.org/10.1186/1753-2000-3-39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796990/
https://www.ncbi.nlm.nih.gov/pubmed/20003260
http://dx.doi.org/10.1186/1753-2000-3-39

Ejemplares similares